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Recent debate and cases involving elite 
athletes raised the question whether or 
not Cannabis sativa (cannabis) should 
be considered doping in sports. Results 
from a 2010 report in the United States 
(Substance Abuse and Mental Health 
Services Administration, 2011) showed 
that cannabis is the most used illicit drug, 
with 17.4 million users smoking cannabis 
and 6.9 million users smoking cannabis on 
a daily or near daily basis. The World Anti-
Doping Agency (WADA) included canna-
bis in its Prohibited List in 2004, claiming 
that cannabis may improve performance in 
some sports and is an illegal drug in most 
countries (Huestis et al., 2011); however, 
the inclusion of a substance in the Code 
(World Anti-Doping Agency, 2009) is 
complex, requiring intense debate among 
delegates and the fulfillment of specific cri-
teria. For instance, Section 4 of the Code 
establishes that a substance be considered 
for inclusion in the Prohibited List if it is 
a masking agent or meets two of the three 
following criteria: (i) potential to enhance 
performance in sports – smoked cannabis 
affects cognition and performance, causes 
memory loss, executive function, and 
motor impairment, among other undesir-
able effect (Saugy et al., 2006). Cannabis 
smoking can be helpful for some activities 
such as extreme sports, as it improves mus-
cle relaxation, reduces anxiety, and extincts 
fear memories (e.g., negative experiences) 
leading to enhanced performance. It is also 
worthwhile to note that cannabis smoking 
improves sleep time and recovery, which 
may favor performance when an athlete 
is facing multiple competitions in a short 
period of time. In light of these positive 
effects, one can assume cannabis is a dop-
ing substance that relaxes the mind and 
improves recovery (Huestis et al., 2011); (ii) 
potential or actual health risk –  cannabis’ 
cognitive effects in chronic users are still 
unclear, but it may downregulate CB1 
receptors, affect executive functions, and 
cause motor impairment, reversed only 
after weeks of abstinence (Hirvonen et al., 
2012). It seems unlikely that athletes are 
chronic cannabis smokers due to the det-
rimental effects of chronic use including 
inconsistent performance, concentration, 
and motivation. Cyclists who smoked can-
nabis had a 1-min decrease in maximal 
exercise performance at 10 min after smok-
ing (Renaud and Cormier, 1986). These 
negative effects on cognition and perfor-
mance can impair critical skills (e.g., deci-
sion making, vigilance, alertness) required 
in high-risk sports to avoid accidents and/
or injuries; or (iii) violation of the spirit 
of sport – doping is essentially contrary to 
the spirit of sport, which is the principle of 
Olympism, characterized by several values, 
such as ethics, fair play and honesty, health, 
respect for rules and laws, and respect for 
self and other participants (World Anti-
Doping Agency, 2009).
Over 60 cannabinoids are present in 
cannabis, with ∆9-tetrahydrocannabinol 
(THC) the main psychoactive constitu-
ent and responsible for the observed toxic 
effects after smoking, while other cannab-
inoids are responsible for minor effects, 
such as cannabinol (CBN), which is 10% 
as psychoactive as THC (Huestis, 2005). 
THC is lipophilic and stores in several 
organs, especially in adipose tissue; this 
extensive body burden explains the pro-
longed cannabinoid detection rate in blood 
and urine for at least 4 weeks in chronic 
daily cannabis smokers (Lowe et al., 2009; 
Bergamaschi et al., 2013). The WADA 
(World Anti-Doping Agency, 2013) estab-
lishes a 15 ng/mL urinary 11-nor-9-car-
boxy-THC (THCCOOH) threshold; urine 
analyses involves THCCOOH-glucuronide 
 conjugates cleavage, which significantly 
increases free THCCOOH concentrations 
and detection time. Urinary THCCOOH 
concentrations above the 15 ng/mL thresh-
old are considered Adverse Analytical 
Findings and may be interpreted as a vio-
lation of anti-doping rules (World Anti-
Doping Agency, 2009). Studies showed 
that even occasional and single cannabis 
smoking might yield a THCCOOH posi-
tive result (≥15 ng/mL) for up to 5 days 
(Huestis et al., 1996). Thus, consuming 
cannabis even weeks before a match may 
imply a considerable risk of being detected 
in a doping test. In light of this considerable 
risk, some users started using a new prep-
aration of herbal smoking blends named 
“Spice.” Such substances are highly potent 
cannabinoid analogs, with unknown and 
potentially harmful toxicological proper-
ties that may cause prolonged intoxication. 
These substances mimic or worsen canna-
bis’ toxic effects provoking cognitive and 
motor impairment (UNODC, 2011).
The non-psychoactive cannabidiol 
(CBD) is anxiolytic in humans following a 
single dose (Zuardi et al., 1993; Bergamaschi 
et al., 2011); decreased anxiety and fear 
memories extinction after oral CBD intake 
may enhance sports performance with no 
“violation” of the Code, as no THCCOOH 
is detected in urine. One way to protect ath-
letes’ health and to promote health, fairness, 
and equality in sports is to include any illicit 
drugs, their constituents and analogs in the 
anti-doping program. The sports may assist 
to create educational program for youth and 
athletes as an alternative to keep them away 
from drugs and to preserve the intrinsic 
value about the “spirit of sport.”
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